COSIRA trial: Enrollment complete for assessing Neovasc Reducer in refractory angina patients -Complete Data from COSIRA Trial Anticipated Around Year's End – -Initial Data from Reducer Patient Registries To Be Presented at EuroPCR 2013 – Neovasc Inc. The COSIRA trial is definitely a double-blinded, randomized, sham-controlled multicenter trial designed to demonstrate the efficacy of the Reducer in a managed people of refractory angina sufferers köpa cialis 10mg . It was conducted in the united kingdom, Europe and Canada. ‘COSIRA was designed as a rigorous study to provide definitive proof the efficacy of the Reducer in enhancing the standard of life of patients with refractory angina, and we look forward to sharing six-month follow-up data from the trial in a peer-reviewed forum around yr's end,’ said Shmuel Banai, MD, Chief Medical Officer of Neovasc.
Kaiser Family Foundation. Copyright 2007 Advisory Board Organization and Kaiser Family Basis. All rights reserved.. CMS proposes increase in Medicare reimbursements for long-term care hospitals CMS on Thursday proposed a 0.71 percent upsurge in standard Medicare reimbursement rates for long-term care hospitals for 2008, CQ HealthBeat reports. Furthermore, CMS proposed to increase the ’25 percent guideline’ – – which reduces Medicare reimbursements for LTCHs located within severe treatment hospitals that accept more than 25 percent of their individuals from the host services – – to cover all LTCHs that accept a lot more than 25 percent of their patients in one medical center.